CEO Share Purchase
Renalytix plc announced that its CEO, James McCullough, purchased 340 American Depositary Shares (ADS) on September 8th and 9th, 2026, at an average price of US$3.875 per ADS, representing a total investment of $1,317.65. Following these transactions, Mr. McCullough now holds 3,447,096 Ordinary Shares, which constitute 0.57% of the company's issued share capital, including shares held through his family trust.
Select text to share a quote on X · sign in to keep highlights & notes in your RENX notes
LONDON and NEW YORK, 11 September 2026 – Renalytix plc (LSE: RENX) (OTCQB: RNLXY), a precision medicine diagnostics company focused on kidney disease, announces that on 8 September 2026 and 9 September 2026 James McCullough, Chief Executive Officer, bought 340 American Depositary Shares (ADS) at an average price of US$3.875 per ADS. ADS consist of 50 Ordinary Shares of £0.0025 each.
Following these purchases, James McCullough is interested in 3,447,096 Ordinary Shares1 representing 0.57% of the issued share capital of the Company.
| a) | Name | James McCullough |
| 2 | Reason for the notification | |
| a) | Position/status | Chief Executive O fficer |
| b) | Initial notification /Amendment | Initial Notification |
| a) | Name | Renalytix plc |
| b) | LEI | 213800NTOH3FK3WER551 |
| a) | Description of the financial instrument, type of instrument | American Depository Shares (ADS) which consist of 50 Ordinary Shares at £0.0025 each |
| Identification code | GB00BYWL4Y04 | |
| b) | Nature of the transaction | Purchase of Ordinary Shares |
| c) | Price(s) and volume(s) | |
| Price(s) | Volume(s) | |
| $3.845 | 250 | 8 September |
| $3 .960 | 9 0 | 9 September |
| d) | Aggregated information | |
| - Aggregated volume | 340 | |
| - Price | $1,317.65 | |
| e) | Date of the transaction | 8 & 9 September 2026 |
| f) | Place of the transaction | OTC New York |
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.